Accelerating the Development and Validation of New Value-Based Diagnostics by Leveraging Biobanks

Area of Science:

• Biomarker Discovery
• Molecular Diagnostics
• Translational Medicine

Background:

• Value-based diagnostics are essential for personalized medicine but face significant development hurdles.
• Current limitations include complex biological understanding, inadequate research infrastructure, and insufficient incentives for diagnostic developers.
• This leads to many patients receiving ineffective therapies, negatively impacting outcomes and healthcare expenditure.

Purpose of the Study:

• To highlight the challenges in developing value-based diagnostics.
• To propose solutions for improving the development and validation of predictive biomarkers.
• To emphasize the critical role of biospecimen access in advancing diagnostic research.

Main Methods:

• Evaluating methodologies for biomarker assessment using biospecimens from randomized clinical trials.
• Leveraging large-scale longitudinal observational cohorts (e.g., UK Biobank, Million Veteran Program) for biospecimen access.
• Utilizing diverse sample types including blood, serum, plasma, urine, and tumor tissue.

Main Results:

• Few value-based diagnostic tests have reached clinical practice due to scientific and infrastructural challenges.
• Enhanced access to high-quality biospecimens linked with clinical data is a key facilitator for biomarker research.
• Methodologies applied to biospecimens from clinical trials and large cohorts offer robust validation pathways.

Conclusions:

• Addressing the paucity of value-based diagnostics requires overcoming complex biology and infrastructure limitations.
• Improved access to well-characterized biospecimens is paramount for developing and validating predictive biomarkers.
• Strategic utilization of existing cohort data and trial biospecimens can accelerate the clinical translation of molecular diagnostics.